Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: A pilot study Influencia de polimorfismos genéticos de cyp3a4/5 en la farmacocinética de levonorgestrel: Estudio piloto

MORENO, IVÁN; QUIÑONES, LUIS; CATALÁN, JOHANNA; MIRANDA, CARLA; ROCO, ÁNGELA; SASSO, JAIME; TAMAYO, EVELYN; CÁCERES, DANTE; TCHERNITCHIN, ANDREI N.; GAETE, LEONARDO; SAAVEDRA, IVÁN

BIOMéDICA

INST NACIONAL SALUD

Año: 2012 vol. 32 p. 570 - 570

0120-4157

ntroduction. Levonorgestrel a synthetic progestagen used for endometriosis, dysmenorrhea and emergency contraception, is quickly and completely absorbed in the digestive tract. levonorgestrel is predominantly metabolised through hepatic routes that utilise the CYP3A system (CYP3A4 and CYP3A5). Objective. This study aimed to evaluate the association between variant alleles of CYP3A4*1B and CYP3A5*3 polymorphisms and the pharmacokinetics of levonorgestrel. Materials and methods. A group of 17 adult female healthy volunteers who signed an informed consent were genotyped for CYP3A4 and CYP3A5 through PCR-RFLP. Volunteers were submitted to pharmacokinetic analysis where, after a 12-hour overnight fast, they received a single oral dose of 0.75 mg of levonorgestrel. Serial blood samples were obtained (0 to 24 hours), and levonorgestrel concentrations were determined by UPLC-MS/MS to determine pharmacokinetic parameters. The procedures employed herein were performed according to the Declarati